Suppr超能文献

多细胞耐药性对实体瘤(包括微转移瘤)存活的影响。

Impact of multicellular resistance on the survival of solid tumors, including micrometastases.

作者信息

Kerbel R S

机构信息

Cancer Research Division, Sunnybrook Health Science Center, Toronto, Ont., Canada.

出版信息

Invasion Metastasis. 1994;14(1-6):50-60.

PMID:7657532
Abstract

One of the reasons for the development of cancers and their relentless malignant progression--even in the face of highly toxic anticancer therapies--is an enhanced ability to bypass mechanisms responsible for precipitating cell death. The latter include active cell death mechanisms often referred to as programmed cell death or apoptosis. Active cell death is a genetically controlled, intrinsic suicide process, and evidence is rapidly accumulating that cancers are more resistant to undergoing apoptosis than normal cells. This may be a major factor explaining the ability of small numbers of tumor cells, e.g. tumor emboli, to survive transit in the bloodstream and form distant metastases in ectopic organ sites. In addition, because many therapeutic agents ultimately kill tumor cells by inducing apoptosis, acquisition of an apoptosis-resistant phenotype could be a generic mechanism of drug or radiation resistance in cancer patients. It follows that uncovering the basis of the enhanced survival capacity of tumor cells is fundamental to gaining a better understanding of tumor progression, metastasis formation, and response to therapy. In this respect many of the principles thought to regulate apoptosis in cancers have been established using conventional, two-dimensional monolayer cell cultures of 'liquid' tumors, i.e. unicellular model systems. Suppression of apoptosis in solid tumors, however, may be governed by different cellular and genetic mechanisms. Evidence is presented in support of this hypothesis, and that multicellular architecture may render individual tumor cells within solid tumors less susceptible to apoptosis. This multicellular resistance--which may represent a form of group protection--can also be induced or acquired during cytotoxic drug chemotherapy or cytokine-mediated growth inhibition of solid tumors. It follows that disruption of solid tumor multicellularity may provide a means of enhancing the therapeutic destruction of small solid tumors such as occult micrometastases. Such disruptions may be brought about by a variety of so-called antiadhesive agents.

摘要

癌症发生发展及其恶性进程难以遏制的原因之一(即使面对高毒性抗癌疗法)是肿瘤细胞规避引发细胞死亡机制的能力增强。这些机制包括常被称为程序性细胞死亡或凋亡的主动细胞死亡机制。主动细胞死亡是一种由基因控制的内在自杀过程,且越来越多的证据表明,癌症细胞比正常细胞更难发生凋亡。这可能是解释少量肿瘤细胞(如肿瘤栓子)能够在血流中存活并在异位器官部位形成远处转移的一个主要因素。此外,由于许多治疗药物最终通过诱导凋亡来杀死肿瘤细胞,获得抗凋亡表型可能是癌症患者产生耐药或放疗抵抗的普遍机制。因此,揭示肿瘤细胞增强的生存能力的基础对于更好地理解肿瘤进展、转移形成及治疗反应至关重要。在这方面,许多被认为调控癌症细胞凋亡的原理是通过对“液体”肿瘤(即单细胞模型系统)进行传统的二维单层细胞培养来确定的。然而,实体瘤中凋亡的抑制可能受不同的细胞和遗传机制支配。本文提供了支持这一假说的证据,即多细胞结构可能使实体瘤中的单个肿瘤细胞更不易发生凋亡。这种多细胞抗性——可能代表一种群体保护形式——也可在实体瘤的细胞毒性药物化疗或细胞因子介导的生长抑制过程中被诱导或获得。因此,破坏实体瘤的多细胞性可能为增强对小实体瘤(如隐匿性微转移灶)的治疗性破坏提供一种方法。这种破坏可由多种所谓的抗黏附剂引起。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验